Harnessing mucosal antibodies against respiratory viral infections
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA400326
Grant search
Key facts
Disease
COVID-19, UnspecifiedStart & end year
20252029Known Financial Commitments (USD)
$419,464.66Funder
National Health and Medical Research Council (NHMRC)Research Location
AustraliaLead Research Institution
University of MelbourneResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnosticsResearch Subcategory
ImmunitySpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
Broad antibody protection could guard against recurring mucosal infections by coronavirus and influenza. However, the antibody types and targeted viral regions driving immunity, particularly at the mucosa, remain unknown. Here, we will identify 1) the antibody features best at protecting against coronavirus and influenza infection, 2) the vaccine platforms most suited to make these antibodies, and 3) if mucosal antibody therapeutics would work against active coronavirus and influenza infections.